Economic evaluation of the familial cancer programme in Western Australia: Predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma

被引:27
作者
Breheny, N [1 ]
Geelhoed, E [1 ]
Goldblatt, J [1 ]
Ee, H [1 ]
O'Leary, P [1 ]
机构
[1] Govt Western Australia, Dept Hlth, Perth, WA, Australia
关键词
colorectal cancer; cost-effectiveness; familial adenomatous polyposis; familial cancer; genetic testing; hereditary non-polyposis colorectal carcinoma; screening; surveillance;
D O I
10.1159/000091487
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aim: To evaluate costs and outcomes of genetic testing for familial colorectal cancer through services provided by Genetic Services of Western Australia (GSWA). Methods: Costs and outcomes of predictive DNA-based testing for inherited colorectal cancers (CRC) were assessed, specifically for familial adenomatous polyposis (FAIR) and hereditary non-polyposis CRC (HNPCC) using a decision-analysis model. Costs were assigned according to standards of care in Western Australia (WA). Cancer risks and the efficacy of surveillance on long-term outcomes were derived from the published literature. Results:The cost-effectiveness of genetic testing was compared in first-degree relatives of known mutation carriers who have a 50% risk of carrying the mutated gene (intervention group) to individuals with the same risk but who do not undergo a genetic test (control subjects). Compared with control subjects undergoing the same high-level surveillance and surgery, the FAP and HNPCC intervention groups provided total savings of $ 13,390 and 14,783-15,460 per person (males-females), respectively. HPNCC mutation carriers also gained 1 CRC-free year. Compared to control subjects having only population surveillance, individuals in the FAP intervention group delayed the onset of CIRC by 40 years for a net cost of $ 9,042. Individuals in the HNPCC intervention group delayed the onset of CIRC by 8 years at a net cost of $12,141 for males and $ 12,596 for females. Conclusions: Genetic testing for familial CRC in WA allows targeted surveillance for mutation carriers, which ensures the efficient use of resources and reduces cancer-related morbidity, if clinical recommendations for intervention are adopted. Copyright (C) 2006 S. Karger AG, Basel.
引用
收藏
页码:98 / 106
页数:9
相关论文
共 27 条
[1]   Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome [J].
Aarnio, M ;
Mecklin, JP ;
Aaltonen, LA ;
NystromLahti, M ;
Jarvinen, HJ .
INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (06) :430-433
[2]  
[Anonymous], CLIN PRACT GUID MAN
[3]  
*AUSTR I HLTH WELF, UNPUB AUSTR I HLTH W
[4]  
*AUSTR I HLTH WELF, 2003, 24 AIHW HWE
[5]  
Australian Institute of Health and Welfare Australasian Association of Cancer Registries, 2003, CANC AUSTR 2000
[6]   FAMILIAL ADENOMATOUS POLYPOSIS (FAP) - FREQUENCY, PENETRANCE, AND MUTATION-RATE [J].
BISGAARD, ML ;
FENGER, K ;
BULOW, S ;
NIEBUHR, E ;
MOHR, J .
HUMAN MUTATION, 1994, 3 (02) :121-125
[7]   The use of gene tests to detect hereditary predisposition to chronic disease: Is cost-effectiveness analysis relevant? [J].
Col, NF .
MEDICAL DECISION MAKING, 2003, 23 (05) :441-448
[8]   Cost analysis of alternative approaches to colorectal screening in familial adenomatous polyposis [J].
Cromwell, DM ;
Moore, RD ;
Brensinger, JD ;
Petersen, GM ;
Bass, EB ;
Giardiello, FM .
GASTROENTEROLOGY, 1998, 114 (05) :893-901
[9]   Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations -: Facts and controversy [J].
Eisen, A ;
Weber, BL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :207-208
[10]   Can APC:: mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis?: Experience from 680 FAP families [J].
Friedl, W ;
Caspari, R ;
Uhlhaas, S ;
Lamberti, C ;
Jungck, M ;
Kadmon, M ;
Wolf, M ;
Fahnenstich, J ;
Gebert, J ;
Möslein, G ;
Mangold, E ;
Propping, P .
GUT, 2001, 48 (04) :515-521